PMID- 21859401
OWN - NLM
STAT- MEDLINE
DCOM- 20120203
LR  - 20131121
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 33
IP  - 9
DP  - 2011
TI  - Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic 
      factors in hemodialysis patients.
PG  - 892-8
LID - 10.3109/0886022X.2011.605536 [doi]
AB  - BACKGROUND: Lipid abnormalities, especially high serum lipoprotein (a) [Lp (a)] 
      concentration, and anemia are two major causes of cardiovascular diseases (CVDs) 
      in hemodialysis patients. Therefore, this study was designed to investigate the 
      effects of marine omega-3 fatty acids on serum lipids, Lp (a), and hematologic 
      factors in hemodialysis patients. METHODS: Thirty-four hemodialysis patients were 
      randomly assigned to either omega-3 fatty acid supplement or placebo group. 
      Patients in the omega-3 fatty acids group received 2080 mg marine omega-3 fatty 
      acids, daily for 10 weeks, whereas the placebo group received a corresponding 
      placebo. At baseline and the end of week 10, 7 mL blood was collected after a 12- 
      to 14-h fast and serum triglyceride, total cholesterol, low-density lipoprotein 
      cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), Lp (a), blood 
      hemoglobin, hematocrit, red blood cells (RBCs), mean corpuscular volume (MCV), 
      mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration 
      (MCHC) were measured. RESULTS: Serum triglyceride decreased significantly in the 
      omega-3 fatty acids group at the end of week 10 compared with baseline (p < 0.05) 
      and this reduction was significant in comparison with the placebo group (p < 
      0.01). No significant differences were observed between the two groups in mean 
      changes of serum total cholesterol, LDL-C, HDL-C, Lp (a), blood hemoglobin, 
      hematocrit, RBC, MCV, MCH, and MCHC. CONCLUSION: The results of our study 
      indicate that marine omega-3 fatty acids can reduce serum triglyceride, as a risk 
      factor for CVD, but it does not affect other serum lipids, Lp (a), and 
      hematologic factors in hemodialysis patients.
FAU - Kooshki, Akram
AU  - Kooshki A
AD  - Department of Nutrition & Biochemistry, Sabzevar University of Medical Sciences, 
      Sabzevar, Islamic Republic of Iran.
FAU - Taleban, Forough Azam
AU  - Taleban FA
FAU - Tabibi, Hadi
AU  - Tabibi H
FAU - Hedayati, Mehdi
AU  - Hedayati M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110823
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Iron Compounds)
RN  - 0 (Lipids)
RN  - 0 (Lipoprotein(a))
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 11096-26-7 (Erythropoietin)
RN  - 935E97BOY8 (Folic Acid)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Cholesterol/*blood
MH  - *Dietary Supplements
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Erythropoietin/therapeutic use
MH  - Fatty Acids, Omega-3/*therapeutic use
MH  - Female
MH  - Folic Acid/therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Iron Compounds/therapeutic use
MH  - Kidney Failure, Chronic/diagnosis/therapy
MH  - Lipids/*blood
MH  - Lipoprotein(a)/blood/*drug effects
MH  - Lipoproteins, HDL/blood/drug effects
MH  - Lipoproteins, LDL/blood/drug effects
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Reference Values
MH  - Renal Dialysis
MH  - Risk Assessment
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/08/24 06:00
MHDA- 2012/02/04 06:00
CRDT- 2011/08/24 06:00
PHST- 2011/08/24 06:00 [entrez]
PHST- 2011/08/24 06:00 [pubmed]
PHST- 2012/02/04 06:00 [medline]
AID - 10.3109/0886022X.2011.605536 [doi]
PST - ppublish
SO  - Ren Fail. 2011;33(9):892-8. doi: 10.3109/0886022X.2011.605536. Epub 2011 Aug 23.